Makary: We Have No Plans to Take Action on Changing Access to Abortion Pill Mifepristone

EXCERPT:

MAKARY: “We’re abiding by that regulation. That means we look at self-reported data in our Adverse Event Reporting Database. It means that when studies suggest that there’s a safety signal in a large administrative database, we have to pay attention to that. For example, there could be a new drug that could have a drug-drug interaction with Mifepristone. So we can’t turn a blind eye to what’s happening with safety signals with that drug or any drug, so that -- that evaluation is ongoing."
VITALI: "But is it still true for you that you have no plans to take action on changing access to that drug?"
MAKARY: "That is true."
VITALI: "Okay."